Ovarian cancer drug trial aims to unlock DNA secrets before surgery

NCT ID NCT02659241

Ongoing Knowledge-focused Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a drug called adavosertib in 38 people with advanced ovarian, fallopian tube, or peritoneal cancer. Participants take the drug for up to 28 days before their scheduled surgery. Researchers will compare tumor DNA before and after treatment to see how the drug affects cancer cells. The goal is not to cure the cancer now, but to learn how the drug works at the DNA level, which could help design better treatments in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: adavosertib (a drug that blocks a protein called Wee1)
What this could lead to: If successful, this study could help doctors understand how adavosertib changes tumor DNA, potentially leading to more effective treatment plans for ovarian cancer.
What could go wrong: This is a very early, small pilot study with only 38 participants. It is designed to measure DNA changes, not to prove the drug works as a treatment. The drug may not affect tumors as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED FALLOPIAN TUBE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma fallopian tube cancer fallopian tube carcinoma fallopian tube neoplasm fallopian tube serous adenocarcinoma ovarian carcinoma ovarian serous adenocarcinoma peritoneal carcinomatosis primary peritoneal carcinoma primary peritoneal serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED FALLOPIAN TUBE CARCINOMA ADVANCED OVARIAN CARCINOMA ADVANCED PRIMARY PERITONEAL CARCINOMA CARCINOMATOSIS FALLOPIAN TUBE HIGH GRADE SEROUS ADENOCARCINOMA OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA STAGE III FALLOPIAN TUBE CANCER AJCC V7 STAGE III OVARIAN CANCER AJCC V6 AND V7 STAGE III PRIMARY PERITONEAL CANCER AJCC V7 STAGE IIIA FALLOPIAN TUBE CANCER AJCC V7 STAGE IIIA OVARIAN CANCER AJCC V6 AND V7 STAGE IIIA PRIMARY PERITONEAL CANCER AJCC V7 STAGE IIIB FALLOPIAN TUBE CANCER AJCC V7 STAGE IIIB OVARIAN CANCER AJCC V6 AND V7 STAGE IIIB PRIMARY PERITONEAL CANCER AJCC V7 STAGE IIIC FALLOPIAN TUBE CANCER AJCC V7 STAGE IIIC OVARIAN CANCER AJCC V6 AND V7 STAGE IIIC PRIMARY PERITONEAL CANCER AJCC V7 STAGE IV FALLOPIAN TUBE CANCER AJCC V6 AND V7 STAGE IV OVARIAN CANCER AJCC V6 AND V7 STAGE IV PRIMARY PERITONEAL CANCER AJCC V7

Contacts and locations

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States
MD Anderson League City

League City, Texas, 77573, United States
MD Anderson West Houston

Houston, Texas, 77079, United States
MD Anderson in Sugar Land

Sugar Land, Texas, 77478, United States
MD Anderson in The Woodlands

Conroe, Texas, 77384, United States
Memorial Hermann Memorial City Medical Center

Houston, Texas, 77024, United States
OHSU Knight Cancer Institute

Portland, Oregon, 97239, United States
The Woman's Hospital of Texas

Houston, Texas, 77054, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.